196170 — Alteogen Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapFalling Star

Market Cap
KR₩20tn
Enterprise Value
KR₩19tn
Revenue
KR₩216bn

Annual income statement for Alteogen, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	38,746	28,806	96,523	102,855	215,859
Cost of Revenue
Gross Profit	5,789	4,531	31,199	64,069	165,625
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	52,033	47,065	104,868	79,971	78,534
Operating Profit	-13,287	-18,259	-8,345	22,884	137,325
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-10,694	-9,970	-3,564	36,612	162,736
Provision for Income Taxes
Net Income After Taxes	-11,588	-10,078	-3,582	60,690	145,173
Minority Interest
Net Income Before Extraordinary Items
Net Income	-6,275	-8,146	-3,372	62,252	141,666
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-6,275	-8,146	-3,372	62,737	139,829
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-124	-301	-57	1,203	2,088
Dividends per Share